肿瘤细胞对DNA拓扑异构酶Ⅰ抑制剂的耐药研究进展
被引量：1
摘要
DNA拓扑异构酶(Topo)抑制剂作为一种新的抗癌靶点,在恶性肿瘤的治疗中有广阔的应用前景,然而耐药性的出现极大限制了其临床应用。Topo分Ⅰ,Ⅱ两型,就Topo Ⅰ抑制剂的耐药机理及可能的逆转途径进行综述。
出处
《国外医学（妇产科学分册）》
CAS
2004年第1期32-35,共4页
Foreign Medical Sciences(Obstet Gynecol Fascicle)
参考文献21
-
1Fukuoka K, Adachi J, Nishio K, et al. p16^INK4 expression is associated with the increased sensitivity of human non-small cell lung cells to DNA topoisomerase Ⅰ inhibitors. Jpn J Cancer Res, 1997, 88 (10):1009-1016.
-
2Desai SD, Li TK, Rodriguez-Bauman A, et al. Ubiquitin/26S proteasome-mediated degradation of topoisomerase Ⅰ as a resistance mechanism to camptothecin in tumor cells. Cancer Res, 2001, 61 (15):5926-5932.
-
3Urasaki Y, Laco GS, Pourquier P, et al. Characterization of a novel topoisomerase Ⅰ mutation from a camptothecin-resistant human prostate cancer cell line. Cancer Res, 2001, 61(5): 1964-1969.
-
4Wang LF, Ting CY, Lo CK, et al. Identification of mutations at DNA topoisomerase Ⅰ responsible for camptothecin resistance. Cancer Res,1997, 57(8): 1516-1522.
-
5Jacob S, Aguado M, Fallik D, et al. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res,2001, 61(17): 6555-6562.
-
6Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A, 1998, 95(26): 15665-15670.
-
7Ma J, Maliepaard M, Nooter K, et al. Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line. Br J Cancer, 1998, 77(10): 1645-1652.
-
8Maliepaard M, van Gastelen MA, de Jong LA, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res, 1999, 59(18): 4559-4563.
-
9Yang CH, Schneider E, Kuo ML, et al. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. BiochemPharmacol, 2000, 60(6): 831-837.
-
10Scheffer GL, Maliepaard M, Pijnenborg AC, et al. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone and topotecan-resistant cell lines. Cancer Res, 2000, 60(10): 2589-2593.
同被引文献5
-
1Chang JY, Liu JF, Juang SH, et al. Novel mutation of topoi-somerase I in rendering cells resistant to camptothecin[ J]. Cancer Res, 2002,62:3716-3721.
-
2Urasaki Y, Iaco GS, Pourquier P, et al. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer ceil line[ J]. Cancer Res, 2001,61:1964-1969.
-
3LaUoo AK, Luo FR, Guo A, et al. Membrane transport of camptothecin: facilitation by human P-glycoprotein( ABCB1 ) and multidrug resistance protein 2 (ABCC2) [ J ]. BMC Med, 2004,2 : 16.
-
4樊代明,刘宪玲.胃癌多药耐药研究新进展[J].中华消化杂志,2000,20(2):77-78. 被引量：5
-
5涂水平,江石湖,谭继宏,钟捷,乔敏敏,蒋晓华,章永平,袁耀宗,吴云林,吴裕炘.羟基喜树碱诱导胃癌细胞凋亡的作用机制初步研究[J].中华消化杂志,2001,21(5):274-277. 被引量：25
-
1孙正怡,沈铿.DNA拓扑异构酶I抑制剂在卵巢癌治疗中的应用[J].中华妇产科杂志,1999,34(6):378-379. 被引量：4
-
2钱其军.烷化剂耐药机制及逆转途径[J].中华血液学杂志,1994,15(8):440-442. 被引量：1
-
3金海燕,陈学艳,程海荣.伊立替康介入治疗晚期直肠癌12例护理体会[J].山东医药,2004,44(8):15-15.
-
4曹晓伟,宋明家.端粒酶与肝癌[J].中国煤炭工业医学杂志,2000,3(8):776-778.
-
5高金波.端粒酶与乳腺癌的研究进展[J].国外医学（外科学分册）,1999,26(6):321-322. 被引量：3
-
6李子辉.CPT-11联合CF及5-Fu治疗老年转移性大肠癌临床观察[J].中国冶金工业医学杂志,2005,22(2):112-112.
-
7谷小燕,杨志敏.伊立替康联合治疗晚期结直肠癌致严重迟发性腹泻的护理[J].中华现代护理杂志,2009,15(15):1442-1443.
-
8谭侃,潘碧云.拓扑替康用于紫杉醇/卡铂化疗后巩固治疗卵巢癌的费用效果分析[J].中国药学杂志,2006,41(13):1036-1038.
-
9陈柯君,吕书晴.雷帕霉素耐药机制及其逆转途径[J].国际肿瘤学杂志,2014,41(10):740-743. 被引量：1
-
10付光新,梁尚争.端粒与端粒酶和口腔颌面部肿瘤[J].泸州医学院学报,2006,29(2):160-162.
